Nebido (R) is an injectable long-acting depot preparation of testosterone undecanoate. Nebido (R) is indicated for testosterone replacement therapy in adult men with confirmed hypogonadism, a ...

Bayer is selling its testosterone treatment Nebido to German pharmaceutical firm Gruenenthal in a deal valued up to 500 million euros ($500.95 million), it said on Thursday. BERLIN, July 14 (Reuters) ...

Apotex and Grünenthal have finalised a licensing agreement granting Apotex exclusive Canadian rights to Nebido, a long-acting ...

German family-owned pain specialist Grünenthal has entered into a licensing agreement whereby Canada-based Apotex will have the exclusive Canadian rights to Nebido (testosterone undecanoate), a ...

LEXINGTON, Mass., June 4 /PRNewswire/ -- Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV) today announced that based on a recent discussion with the U.S. Food and Drug Administration (FDA) regarding the ...

AACHEN, Germany, July 14, 2022 /PRNewswire/ -- Grünenthal, a global science-based, privately-owned pharmaceutical company, today announced an agreement with Bayer AG to acquire Nebido TM, the ...

Apotex Inc. ("Apotex"), the largest Canadian-based pharmaceutical company, and Grünenthal, a global leader in pain management ...

BERLIN (Reuters) - Bayer is selling its testosterone treatment Nebido to German pharmaceutical firm Gruenenthal in a deal valued up to 500 million euros ($500.95 million), it said on Thursday. BERLIN ...

Grünenthal acquires Nebido TM from Bayer AG for up to € 500 million. The product is expected to add about € 100 million to Grünenthal's EBITDA in 2023. Nebido TM is the gold standard for the treatment ...